Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development and Validation of Prognostic Model for Metastatic Castration-Resistant Prostate Cancer Patients Treated With First-Line Abiraterone or Enzalutamide.
Caffo O, Basso U, Cattrini C, Ermacora P, Maruzzo M, Alberti M, Anesi C, Bimbatti D, Cani M, Crespi V, Farinea G, Kadrija D, Kinspergher S, Lai E, Lay L, Maines F, Mennitto A, Pierantoni F, Samuelly A, Urban S, Buttigliero C, Veccia A. Caffo O, et al. Among authors: buttigliero c. Clin Genitourin Cancer. 2024 Nov 12;23(1):102265. doi: 10.1016/j.clgc.2024.102265. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 39662149
Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era.
Tucci M, Caffo O, Buttigliero C, Cavaliere C, D'aniello C, Di Maio M, Kinspergher S, Maines F, Rizzo M, Rossetti S, Veccia A, Scagliotti GV, Facchini G. Tucci M, et al. Among authors: buttigliero c. Cancer Treat Rev. 2019 Mar;74:35-42. doi: 10.1016/j.ctrv.2019.01.002. Epub 2019 Jan 7. Cancer Treat Rev. 2019. PMID: 30738364 Free article. Review.
Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer.
Caffo O, Facchini G, Biasco E, Ferraù F, Morelli F, Donini M, Buttigliero C, Calvani N, Guida A, Chiuri VE, Basso U, Mucciarini C, Conteduca V, Rossetti S, Veccia A, Maines F, Kinspergher S, De Giorgi U. Caffo O, et al. Among authors: buttigliero c. Future Oncol. 2019 Apr;15(10):1115-1123. doi: 10.2217/fon-2018-0715. Epub 2019 Mar 19. Future Oncol. 2019. PMID: 30887825
The prognostic value of pain in castration-sensitive prostate cancer.
Iacovelli R, Ciccarese C, Caffo O, De Giorgi U, Tucci M, Mosillo C, Bimbatti D, Pierantoni F, Maines F, Casadei C, Buttigliero C, Milella M, Tortora G. Iacovelli R, et al. Among authors: buttigliero c. Prostate Cancer Prostatic Dis. 2020 Dec;23(4):654-660. doi: 10.1038/s41391-020-0255-x. Epub 2020 Jul 10. Prostate Cancer Prostatic Dis. 2020. PMID: 32651468
TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis.
Pisano C, Turco F, Arnaudo E, Fea E, Vanella P, Ruatta F, Filippi R, Brusa F, Prati V, Vana F, Mennitto A, Cattrini C, Vignani F, Dionisio R, Icardi M, Guglielmini P, Buosi R, Stevani I, Vormola R, Numico G, Depetris I, Comandone A, Gennari A, Airoldi M, Rossi M, Vellani G, Ortega C, Tucci M, Maio MD, Buttigliero C. Pisano C, et al. Among authors: buttigliero c. Clin Genitourin Cancer. 2024 Apr;22(2):56-67.e16. doi: 10.1016/j.clgc.2023.08.006. Epub 2023 Sep 7. Clin Genitourin Cancer. 2024. PMID: 37798164
Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives.
Turco F, Buttigliero C, Delcuratolo MD, Gillessen S, Vogl UM, Zilli T, Fossati N, Gallina A, Farinea G, Di Stefano RF, Calabrese M, Saporita I, Crespi V, Poletto S, Palesandro E, Di Maio M, Scagliotti GV, Tucci M. Turco F, et al. Among authors: buttigliero c. Clin Genitourin Cancer. 2024 Oct;22(5):102138. doi: 10.1016/j.clgc.2024.102138. Epub 2024 Jun 12. Clin Genitourin Cancer. 2024. PMID: 38996529 Review.
Testing BRCA 1-2 Mutations in Metastatic Prostate Cancer: Results of a Survey of the Italian Association of Medical Oncology.
Saporita I, Calabrese M, Poletto S, Turco F, Di Stefano RF, Caffo O, Russo A, De Giorgi U, Tucci M, Di Maio M, Cinieri S, Buttigliero C. Saporita I, et al. Among authors: buttigliero c. Clin Genitourin Cancer. 2024 Nov 1;23(1):102255. doi: 10.1016/j.clgc.2024.102255. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 39615118
Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study.
Caffo O, De Giorgi U, Fratino L, Alesini D, Zagonel V, Facchini G, Gasparro D, Ortega C, Tucci M, Verderame F, Campadelli E, Lo Re G, Procopio G, Sabbatini R, Donini M, Morelli F, Sartori D, Zucali P, Carrozza F, D'Angelo A, Vicario G, Massari F, Santini D, Sava T, Messina C, Fornarini G, La Torre L, Ricotta R, Aieta M, Mucciarini C, Zustovich F, Macrini S, Burgio SL, Santarossa S, D'Aniello C, Basso U, Tarasconi S, Cortesi E, Buttigliero C, Ruatta F, Veccia A, Conteduca V, Maines F, Galligioni E. Caffo O, et al. Among authors: buttigliero c. Eur Urol. 2015 Jul;68(1):147-53. doi: 10.1016/j.eururo.2014.10.014. Epub 2014 Oct 25. Eur Urol. 2015. PMID: 25457020
98 results